Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxyne Limited ( (AU:BXN) ) has issued an announcement.
Bioxyne Limited has secured a $7 million manufacturing and supply agreement with NectarTek, an Australian healthcare company. This deal, which marks a 200% revenue increase from the previous year, appoints BLS as the exclusive manufacturer for NectarTek’s products in Australia, the UK, and Germany, enhancing Bioxyne’s market position and potential for future contracts.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical and consumer health products company, known for its subsidiary Breathe Life Sciences (BLS). The company specializes in manufacturing and supplying alternative pharmaceuticals, including cannabis products for authorized prescribers and clinical trials in both domestic and international markets.
YTD Price Performance: -13.33%
Average Trading Volume: 3,465,707
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$60.62M
See more insights into BXN stock on TipRanks’ Stock Analysis page.